The Pharmacology of Dermal Fibrosis

真皮纤维化的药理学

• 批准号: 7565175
• 负责人: BRUCE Neil CRONSTEIN
• 金额: $ 37.29万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-01-15 至 2013-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7565175
• 关键词: 5' -Nucleotidase; Adenosine; Adenosine A2A Receptor; Adenosine A2B Receptor; Animal Model; Animals; Bleomycin; Cell physiology; Cells; Cicatrix; Clinic; Collagen; Complex; Connective Tissue; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dermal; Development; Diffuse; Diffuse Scleroderma; Disease; Experimental Models; Fibroblasts; Fibrosis; Future; Genetic Transcription; Growth; Growth Factor; Hepatic; Hepatic Stellate Cell; Hypertrophic Cicatrix; Hypoxia; In Vitro; Interferons; Interleukin-13; Interleukin-4; Keloid; Knockout Mice; Laboratories; Lead; Life; Liver Cirrhosis; Liver Fibrosis; Lung; MAPK14 gene; Mediating; Medical; Methods; Modeling; Molecular; Morbidity - disease rate; Mus; New Agents; Nuclear; Organ; Pathologic; Pathway interactions; Pharmacology; Platelet-Derived Growth Factor; Play; Process; Production; Pulmonary Fibrosis; Purine Nucleosides; Purinergic P1 Receptors; Radiation Pneumonitis; Regulation; Reporting; Research Design; Role; Scleroderma; Signal Pathway; Signal Transduction; Skin; Small Interfering RNA; TNF gene; Techniques; Tendon structure; Thioacetamide; Tissues; Toxin; Wound Healing; adenosine deaminase; clinically relevant; cytokine; extracellular; fibrosing agent; in vivo; interleukin-13 receptor; mortality; nucleoside triphosphate; prevent; public health relevance; pyrophosphatase; receptor; receptor expression; receptor function; repaired; research study; small molecule; src-Family Kinases; therapy development

DESCRIPTION (provided by applicant): Matrix replacement and repair is required for wound healing but when the process is overly exuberant, as in scar or keloid formation, or when it occurs inappropriately, as in Scleroderma and other fibrosing diseases, it can lead to morbidity and, in the case of Scleroderma, mortality. Although it is clear that growth factors play a central role in fibrosis the role of small molecules in pathologic fibrosis has not been well explored. We have recently demonstrated that the purine nucleoside adenosine, acting through the adenosine A2A receptor, plays a central role in the fibrosis that develops in experimental models of hepatic cirrhosis and scleroderma. We propose here to further determine whether adenosine and adenosine receptors play a role in pathologic fibrosis and to dissect the molecular mechanism by which adenosine A2A receptors on fibroblasts stimulate overproduction of collagen and other matrix constituents. To this end we have proposed to study: I. The role of adenosine receptors in pathologic fibrosis. We will study the development of hypertrophic scarring in a model of dermal scarring and diffuse dermal fibrosis induced by bleomycin treatment in wild type, adenosine A1, A2A, A2B and A3 receptor knockout mice, mice that generate less extracellular adenosine (ecto-5'Nucleotidase and nucleoside triphosphate pyrophosphatase knockout mice) and mice treated with adenosine receptor antagonists; II. Signaling at adenosine A2A receptors for fibrosis In preliminary experiments we have observed that adenosine A2A receptor stimulation diminishes nuclear fli1 levels, a constitutive repressor of CTGF expression, a change which may mediate the pro- fibrotic effects of adenosine and the A2A receptor. We will dissect the signaling pathways from adenosine A2A receptors to suppression of fli1 expression and nuclear localization using a combination of pharmacologic and siRNA-mediated knockdown techniques; III. Cross-talk between adenosine A2A receptors and receptors for "anti-fibrotic" cytokines We have previously demonstrated that interferon-3, an anti-fibrotic cytokine, diminishes adenosine A2A receptor expression and, more dramatically, function. We will study the mechanism by which interferon-3 downregulates adenosine A2A receptor function with a combination of pharmacologic and molecular (siRNA-mediated knockdown) methods. In future experiments we will examine the role of adenosine receptors in keloid formation and other clinically- relevant forms of pathologic fibrosis (e.g. radiation fibrosis). Because adenosine receptor antagonists are under development for the treatment of a variety of medical conditions it may be possible to quickly bring the information garnered in these studies to the clinic. PUBLIC HEALTH RELEVANCE: The synthesis of new fibrous tissue is a normal process which is critical for wound healing and tissue repair, however excess fibrous tissue formation is a significant medical issue in conditions ranging from Scleroderma (diffuse skin and organ fibrosis that can be life-threatening) to disfiguring scarring or tendon enlargement. Our laboratory has found that adenosine and its receptors play a central role in diffuse fibrosis in animal models of Scleroderma and hypertrophic scarring. We propose studies designed to further confirm the role of adenosine and its receptors in scarring and to discover the mechanism by which adenosine receptors stimulate production of excess fibrous tissue. A better understanding of the role of adenosine and its receptors in fibrosis and the medical problems resulting from fibrosis could facilitate the development of new agents that will prevent the development of enlarged scars or ameliorate the fibrosis that characterizes Scleroderma.

描述（由申请人提供）：基质置换和修复是伤口愈合所需的，但当该过程过度旺盛时，如在瘢痕或瘢痕疙瘩形成中，或当其不适当地发生时，如在硬皮病和其他纤维化疾病中，其可导致发病率，并且在硬皮病的情况下，可导致死亡率。虽然生长因子在纤维化中起着重要作用，但小分子在病理性纤维化中的作用还没有得到很好的研究。我们最近证明，嘌呤核苷腺苷，通过腺苷A2 A受体，发挥了核心作用，在肝硬化和硬皮病的实验模型中发展的纤维化。我们建议进一步确定腺苷和腺苷受体是否在病理性纤维化中发挥作用，并剖析成纤维细胞上的腺苷A2 A受体刺激胶原蛋白和其他基质成分过度产生的分子机制。为此，我们建议研究：一。腺苷受体在病理性纤维化中的作用。我们将在野生型、腺苷A1、A2 A、A2 B和A3受体敲除小鼠、产生较少细胞外腺苷的小鼠（外-5 '核苷酸酶和核苷三磷酸焦磷酸酶敲除小鼠）和用腺苷受体拮抗剂治疗的小鼠中研究由博来霉素治疗诱导的皮肤瘢痕形成和弥漫性皮肤纤维化模型中肥大性瘢痕形成的发展; II.在腺苷A2 A受体上的纤维化信号传导在初步实验中，我们观察到腺苷A2 A受体刺激降低了核fil 1水平，核fil 1是CTGF表达的组成性阻遏物，这种变化可能介导腺苷和A2 A受体的促纤维化作用。我们将使用药理学和siRNA介导的敲低技术的组合来剖析从腺苷A2 A受体到抑制fli 1表达和核定位的信号通路; III.腺苷A2 A受体与“抗纤维化”细胞因子受体之间的相互作用我们先前已经证明干扰素-3（一种抗纤维化细胞因子）减少腺苷A2 A受体表达，并且更显著地减少其功能。我们将研究干扰素-3下调腺苷A2 A受体功能的药理学和分子（siRNA介导的敲除）方法相结合的机制。在未来的实验中，我们将研究腺苷受体在瘢痕疙瘩形成和其他临床相关形式的病理性纤维化（如放射性纤维化）中的作用。由于腺苷受体拮抗剂正在开发中，用于治疗各种医学疾病，因此有可能快速将这些研究中获得的信息应用于临床。公共卫生关系：新的纤维组织的合成是一个正常的过程，这对于伤口愈合和组织修复至关重要，然而，过量的纤维组织形成是从硬皮病（可能危及生命的弥漫性皮肤和器官纤维化）到毁容疤痕或肌腱肿大的疾病中的一个重要的医学问题。我们的实验室已经发现腺苷及其受体在硬皮病和增生性瘢痕的动物模型中的弥漫性纤维化中起核心作用。我们提出的研究旨在进一步证实腺苷及其受体在瘢痕形成中的作用，并发现腺苷受体刺激产生过量纤维组织的机制。更好地了解腺苷及其受体在纤维化中的作用以及由纤维化引起的医学问题可以促进新药物的开发，这些新药物将防止瘢痕扩大的发展或改善硬皮病的纤维化特征。